RenovoRx, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (20)

View All

Latest Posts

About This Stock More About This Stock
RenovoRx Announces Positive New Data From Phase III Clinical Trial Interim Analysis: 60% Survival Benefit And Fewer Side Effects Than Systemic Chemotherapy
Article By: TalkMarkets Newswire
Thursday, March 30, 2023 12:18 PM EDT
RenovoGem patients had greater than 65% reduction in side effects, which can include nausea, fatigue, and reduced white blood cells during pancreatic cancer treatment.
In this article: RNXT
Read
RenovoRx’s Principal Investigator Of Phase III Clinical Trial Discusses Positive Interim Results On Patients With Locally Advanced Pancreatic Cancer On OncologyTube
Video By: TalkMarkets Newswire
Tuesday, March 21, 2023 11:26 AM EDT
In the interview, Dr. Michael Pishvaian discussed the trial's potential impact on the oncology community as well as how pancreatic cancer patients are treated.
In this video: RNXT
Watch
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation Of RenovoGemTM As A Treatment Option For Locally Advanced Pancreatic Cancer
Article By: Business Wire
Wednesday, March 8, 2023 8:23 AM EDT
Renovo RX today announced promising interim data in the Phase III open label TIGeR-PaC clinical trial.
In this article: RNXT
Read
RenovoRX's Latest Innovative Technology Creates New Hope For Chemotherapy Patients
Article By: Shareholders Unite
Tuesday, February 28, 2023 11:15 PM EDT
RenovoRx takes existing chemotherapies and makes them more effective and less invasive, by being able to concentrate most of the chemotherapy agent on the tumor itself.
In this article: RNXT
Read
All Posts

Latest Tweets for $RNXT

No tweets yet!

PARTNER HEADLINES

$RNXT

Comments Status Updates
RenovoRX's Latest Innovative Technology Creates New Hope for Chemotherapy Patients
Susan Miller • 2/14/2023 4:24:46 PM

Definitely good news for cancer patients.... and $RNXT stock!

1 to 1 of 1 comments